Compare Crown Castle International Corp (CCI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs TG Therapeutics Inc — how do they compare? Crown Castle International Corp trades at $73.76 (market cap $31.33B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Crown Castle International Corp is far larger — about 4.1× TG Therapeutics Inc's market cap, and Crown Castle International Corp pays a 5.77% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CCI | TGTX | |
|---|---|---|
Market Cap | $31.33B | $7.64B |
Sector | Real Estate | Health |
52-Week High | $103.79 | $59.06 |
52-Week Low | $73.61 | $26.94 |
Enterprise Value | $53.69B | $7.84B |
Dividend Yield | 5.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $73.98, near 52-week lows, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 AFFO of $1.13 per share, beating estimates, and raised full-year guidance amid its transition to a pure-play U.S. tower operator. Revenue declined to $4.26B in 2025 but profitability improved with 20.72% net margin. Analyst consensus remains divided with 50% buy ratings and $95.29 price target suggesting 29% upside.
The stock presents a value opportunity with discounted valuation and 5.5% dividend yield, but faces headwinds from high debt levels (77.21% debt-to-asset ratio) and competitive pressure in the tower REIT sector. Recent institutional selling and technical weakness indicate near-term caution despite long-term growth potential from wireless infrastructure demand.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
